Pharmacokinetic study of aldoxorubicin in patients with solid tumors
详细信息 查看全文
- 作者：Monica M. Mita (1)
Ronald B. Natale (1)
Edward M. Wolin (1)
Brenda Laabs (1)
Hillary Dinh (2)
Scott Wieland (2)
Daniel J. Levitt (2)
Alain C. Mita (1)
1. Samuel Oschin Comprehensive Cancer Institute ; Cedars-Sinai Medical Center ; 8700 Beverly Boulevard ; Suite MS31 ; Los Angeles ; CA ; 90048 ; USA
2. CytRx Corporation ; 11726 San Vicente Boulevard ; Suite 650 ; Los Angeles ; CA ; 90049 ; USA - 关键词：Doxorubicin ; Doxorubicinol ; Pharmacokinetics ; Prodrugs ; Serum albumin
- 刊名：Investigational New Drugs
- 出版年：2015
- 出版时间：April 2015
- 年：2015
- 卷：33
- 期：2
- 页码：341-348
- 全文大小：446 KB
- 参考文献：1. Doxorubicin hydrochloride [prescribing information] (2010) Bedford, OH: Bedford Laboratories
2. National Cancer Institute (2013) Cancer drug information: Doxorubicin hydrochloride. http://www.cancer.gov/cancertopics/druginfo/doxorubicinhydrochloride/print. Accessed 29 September 2014.
3. Lefrak, EA, Pitha, J, Rosenheim, S, Gottlieb, JA (1973) A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32: pp. 302-314 CrossRef
4. Hoff, DD, Layard, MW, Basa, P, Davis, HL, Hoff, AL, Rozencweig, M, Muggia, FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: pp. 710-717 CrossRef
5. Boucek, RJ, Olson, RD, Brenner, DE, Ogunbunmi, EM, Inui, M, Fleischer, S (1987) The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. a correlative study of cardiac muscle with isolated membrane fractions. J Biol Chem 262: pp. 15851-15856
6. Tacca, M, Danesi, R, Ducci, M, Bernardini, C, Romanini, A (1985) Might adriamycinol contribute to adriamycin-induced cardiotoxicity?. Pharmacol Res Commun 17: pp. 1073-1084 CrossRef
7. Kratz, F, Warnecke, A, Scheuermann, K, Stockmar, C, Schwab, J, Lazar, P, Druckes, P, Esser, N, Drevs, J, Rognan, D, Bissantz, C (2002) Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J Med Chem 45: pp. 5523-5533 CrossRef
8. Maeda, H, Wu, J, Sawa, T, Matsumura, Y, Hori, K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65: pp. 271-284 CrossRef
9. Unger, C, Haring, B, Medinger, M, Drevs, J, Steinbild, S, Kratz, F, Mross, K (2007) Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin. Clin Cancer Res 13: pp. 4858-4866 CrossRef
10. Smith, TJ, Khatcheressian, J, Lyman, GH, Ozer, H, Armitage, JO, Balducci, L, Bennett, CL, Cantor, SB, Crawford, J, Cross, SJ, Demetri, G (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24: pp. 3187-3205 CrossRef - 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Oncology
Pharmacology and Toxicology - 出版者：Springer Netherlands
- ISSN：1573-0646
文摘